These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 23681436)

  • 1. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
    Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
    AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanism of action and pharmacokinetics of rilpivirine].
    Portilla J; Estrada V
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():2-5. PubMed ID: 24252527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.
    Sharma M; Saravolatz LD
    J Antimicrob Chemother; 2013 Feb; 68(2):250-6. PubMed ID: 23099850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilpivirine (Edurant)--a new drug for HIV infection.
    Med Lett Drugs Ther; 2011 Aug; 53(1371):67-8. PubMed ID: 21860365
    [No Abstract]   [Full Text] [Related]  

  • 6. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.
    Ripamonti D; Bombana E; Rizzi M
    Expert Rev Anti Infect Ther; 2014 Jan; 12(1):13-29. PubMed ID: 24308712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.
    Prescrire Int; 2012 Nov; 21(132):262-5. PubMed ID: 23210255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
    De Clercq E
    Biochem Pharmacol; 2012 Aug; 84(3):241-8. PubMed ID: 22504027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
    James C; Preininger L; Sweet M
    Am J Health Syst Pharm; 2012 May; 69(10):857-61. PubMed ID: 22555080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
    Imaz A; Podzamczer D
    AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Ripamonti D; Maggiolo F
    Curr Opin Investig Drugs; 2008 Aug; 9(8):899-912. PubMed ID: 18666038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.
    Crauwels HM; van Heeswijk RP; Vandevoorde A; Buelens A; Stevens M; Hoetelmans RM
    J Clin Pharmacol; 2014 Feb; 54(2):133-40. PubMed ID: 24203510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
    Crauwels HM; van Heeswijk RP; Buelens A; Stevens M; Hoetelmans RM
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):118-28. PubMed ID: 24161160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
    Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
    Antivir Ther; 2010; 15(6):817-29. PubMed ID: 20834094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
    Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
    Kakuda TN; Leopold L; Nijs S; Vandevoorde A; Crauwels HM; Bertelsen KM; Stevens M; Witek J; van Delft Y; Tomaka F; Hoetelmans RM
    J Clin Pharmacol; 2014 May; 54(5):563-73. PubMed ID: 25975423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic interactions].
    Arazo Garcés P; de los Santos Gil I
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():12-9. PubMed ID: 24252529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Conclusions. Position of rilpivirine in the management of infection by the human immunodeficiency virus].
    Podzamczer D
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():44. PubMed ID: 24252533
    [No Abstract]   [Full Text] [Related]  

  • 20. [RILPIVIRINE -- a novel HIV-1 non-nucleoside reverse transcriptase inhibitor].
    Snopková S; Havlíčková K; Polák P; Šlesinger P; Husa P
    Klin Mikrobiol Infekc Lek; 2013 Mar; 19(1):19-22. PubMed ID: 23945833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.